



Meet the Expert

Dr. Luc Furic

Head of Translational Prostate Cancer Research,
Peter MacCallum Cancer Centre, Melbourne, Australia
Head of the BDI's Prostate Cancer laboratory,
Monash University, Monash, Australia



Dr. Furic is a basic and translational research scientist. He was awarded his PhD in Biochemistry from University of Montreal, Canada, for his discovery of a novel RNA degradation mechanism. During his postdoctoral training in Molecular and Cancer Cell Biology at McGill University, Canada, under the mentorship of Professor Nahum Sonenberg, he identified the translation initiation factor eIF4E as a key driver in prostate cancer. In 2011, he relocated to Monash University, Australia to pursue his research on prostate cancer.

Major Research Interests

Dr. Furic's current research focuses on oncogenic signalling in prostate cancer, especially signaling impacting protein synthesis, and the identification and validation of novel therapeutic targets. Dr. Furic has made key discoveries in understanding the reprogramming of protein synthesis as a vulnerability in prostate cancer. The overarching goal of his research program is to identify and target molecular pathways which are activated in all prostate cancer cells to address the challenge of tumour heterogeneity. His research has recently identified tRNA epitranscriptomic modifications as a vulnerability in prostate cancer. His laboratory uses biochemical and molecular biology approaches to gain a better understanding of the molecular mechanisms responsible for prostate cancer progression. He has significant experience in developing and working with genetically engineered mouse models (GEMM) and patient-derived xenografts (PDX) of prostate cancer for pre-clinical drug testing. Dr. Furic is an Associate Investigator of the recently inaugurated ProSTIC Theranostics Centre at the Peter MacCallum Cancer Centre.

Relation to Asian Journal of Andrology

I have been a guest reviewer for AJA since 2013 and became member of the Editorial Board in 2019. AJA has a rigorous peer review process and publishes timely articles and reviews in the field of prostate cancer.

(Dr. Luc Furic has won 2020 AJA Outstanding Reviewer Award; May 2021)